Analyst Price Targets — AI
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 4, 2026 11:59 am | — | UBS | $12.00 | $10.81 | TheFly | C3 AI price target raised to $12 from $9 at UBS |
| June 4, 2026 11:27 am | Sanjit Singh | Morgan Stanley | $7.00 | $10.71 | TheFly | C3 AI price target raised to $7 from $6 at Morgan Stanley |
| June 4, 2026 10:47 am | — | Canaccord Genuity | $10.00 | $10.71 | TheFly | C3 AI price target raised to $10 from $8 at Canaccord |
| May 13, 2026 11:18 am | — | Canaccord Genuity | $8.00 | $8.79 | TheFly | C3 AI price target raised to $8 from $7 at Canaccord |
| February 26, 2026 1:22 pm | — | Gordon Haskett Capital Corporation | $7.00 | $8.14 | StreetInsider | c3.ai (AI) PT Lowered to $7 at Canaccord |
| February 26, 2026 1:22 pm | — | BMO Capital | $7.00 | $8.14 | StreetInsider | c3.ai (AI) PT Lowered to $7 at Canaccord |
| February 26, 2026 1:13 pm | Lucky Schreiner | D.A. Davidson | $7.00 | $8.18 | StreetInsider | c3.ai (AI) PT Lowered to $7 at DA Davidson as Revenue Growth to Decline Significantly |
| February 26, 2026 1:03 pm | Gal Munda | Wolfe Research | $6.00 | $8.15 | StreetInsider | c3.ai (AI) PT Lowered to $6 at Wolfe Research |
| January 30, 2026 10:26 am | — | Oppenheimer | $10.00 | $12.26 | StreetInsider | c3.ai (AI) PT Lowered to $10 at BofA Securities |
| September 9, 2025 10:11 am | Sanjit Singh | Morgan Stanley | $11.00 | $15.74 | TheFly | C3 AI price target lowered to $11 from $22 at Morgan Stanley |
Latest News for AI
CEO Thomas Siebel executed the sale of 462,565 shares for ~$4.2 million at a weighted average price of $9.18 per share. The disposition reduced the executive's direct equity position by 39%.
In the closing of the recent trading day, C3.ai, Inc. (AI) stood at $8.91, denoting a -2.52% move from the preceding trading day.
On the July 16 episode of The Investing for Beginners Podcast, co-host Stephen Morris drew a hard line around AI stocks, arguing investors should stay away from anything the government will regulate.
[url="]The Hackett Group, Inc.[/url] (NASDAQ: HCKT), an ROI-led AI transformation firm, today released new research examining how artificial intelligence (AI)
Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has signed an agreement with Toronto-based Biossil, Inc. for the sale of ridinilazole, an investigat
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AI.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.